Sunday, September 2
| 13:00 – 15:00 | Eli Lilly Satellite Symposium: Overcoming Challenges in Treating Thoracic Cancers |
| 15:30 – 17:30 | AstraZeneca Satellite Symposium: IRESSA: A Journey of Experience |
Monday, September 3
| 07:00 – 08:00 | GlaxoSmithKline Satellite Symposium: Breakthrough strategies and a new approach in the treatment of lung cancer |
| Merck Serono Satellite Symposium: Future treatment strategies for Non Small Cell Lung Cancer | |
| Novartis Satellite Symposium: Current and Emerging Therapies for Patients with Lung Cancer - Preserving Functional Independence and Improving Outcomes | |
| 12:00– 13:30 | sanofi-aventis Satellite Symposium: Improving overall Survival and QoL in Patients with NSCLC *Lunch served at 12:00 |
| 17:45 – 19:15 | Roche / Genentech / OSI Pharmaceuticals Satellite Symposium: Myths and Facts: Tarceva in second-line NSCLC |
| 18:00 – 19:30 | AstraZeneca Satellite Symposium: Targeted Therapies in Lung Cancer: Creating Options for Patients |
Tuesday, September 4
| 07:00 – 08:00 | Boehringer Ingelheim Satellite Symposium: 2nd Generation TKI's in Patients with EGFR Mutations |
| Pfizer Satellite Symposium: Targeting Multiple Pathways in Lung Cancer Therapy | |
| Bayer Schering Satellite Symposium: The Emerging Role of Multi-Kinase Inhibitors in Non-Small Cell Lung Cancer |
|
| 12:15 – 13:30 | Eli Lilly Satellite Symposium: The Relentless Pursuit of Progress in Thoracic Oncology |
| 17:45 – 19:15 | Roche / Genentech / OSI Pharmaceuticals Satellite Symposium: Establishing a new Treatment Standard: The Evolution of Anti-Angiogenic Agents |
Wednesday, September 5
| 06:45– 08:00 | sanofi-aventis Satellite Symposium: Debating Treatment Strategies for NSCLC |
| 07:00 – 08:00 | Bristol-Myers Squibb Satellite Symposium: Innovative Strategies for Targeting EGFR in NSCLC |
